retatrutide trial results Shows Promising in Type 2 Diabetes and Obesity | Michael Weintraub, MD posted on the topic Interesting data from the @EliLillyandCo

During the CNBC interview, FDA Commissioner Makary remarked that he hopes 2026 will see the end of unlawful mass compounding of GLP-1s

(available at: [Google Scholar] 73.Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson Jet al

Oral pill, easier to take

All injections are provided directly at the clinic or can be taken home depending on patient preference

The mechanisms get muddled, the GH side effects show up, and the metabolic gain from MOTS-C gets harder to isolate

Over time, as new studies are released, additional options for managing side effects may arise